Clinicians' recognition of the metabolic adverse effects of antipsychotic medications

Schizophr Res. 2005 Nov 15;79(2-3):281-8. doi: 10.1016/j.schres.2005.04.010. Epub 2005 Jun 20.


There is a growing concern regarding the propensity of second generation antipsychotics (SGAs) to induce weight gain and metabolic adverse effects. Recent consensus guidelines have recommended assessment and monitoring procedures to appropriately detect and manage these adverse effects. This study addresses the appreciation and readiness of clinicians to implement management guidelines for these adverse effects. Respondents indicated awareness of the risks of treatment with SGAs. The extent of monitoring for metabolic adverse effects was low and inconsistent across measures and in frequency of evaluation. Ongoing efforts are needed to support and encourage change in clinician practice.

Publication types

  • Comparative Study

MeSH terms

  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects*
  • Drug Monitoring
  • Humans
  • Metabolic Diseases / chemically induced*
  • Metabolic Diseases / classification
  • Recognition, Psychology / drug effects*
  • Review Literature as Topic
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism*
  • Surveys and Questionnaires
  • Weight Gain / drug effects*


  • Antipsychotic Agents